Therma Bright (TSE:THRM)
:THRM
THRM Stock Chart & Stats
C$0.06
>-C$0.01(-12.50%)
At close: 4:00 PM EST
C$0.06
>-C$0.01(-12.50%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.24
Previous CloseN/A
Volume10.00K
Average Volume (3M)50.06K
Market Cap
C$3.19M
Enterprise ValueC$3.21M
Total Cash (Recent Filing)C$65.59K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Apr 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,002,876
10 Day Avg. Volume51,225
30 Day Avg. Volume50,057
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables PotentialThe company’s revenue model includes consumable diagnostic tests with potential recurring reorders. Durable consumable demand can create predictable, repeatable revenue and higher lifetime customer value if adoption grows, improving cash flow stability over months.
Product-focused Medical DevicesTherma Bright’s focused product set (non-contact screening and diagnostics) aligns with structural healthcare needs for infection screening and point-of-care testing. A clear product-market fit supports sustained demand from institutional customers and repeat purchases over the medium term.
Low Reported Financial LeverageMinimal reported debt reduces interest burden and near-term solvency pressure, giving management flexibility to pursue commercialization or raise non-debt capital. Lower leverage preserves operational optionality during continued scaling and product commercialization phases.
Bears Say
Tiny And Declining RevenueTTM revenue is extremely small and has declined year-over-year, indicating the business lacks scale. Without material top-line growth, fixed costs and R&D overhead will pressure margins and hinder the company’s ability to achieve sustainable, self-funded operations over the medium term.
Persistent Negative Cash FlowSustained negative operating and free cash flow means the company is burning cash and not yet self-sustaining. Continued cash burn will likely force external financing, constraining strategic options and risking dilution or interrupted investment in commercialization and product development.
Negative Shareholders' EquityNegative equity reflects accumulated losses and impairs financial flexibility. It can complicate access to capital, reduce creditor confidence, and limit the company’s ability to absorb shocks or invest in growth initiatives without dilutive financings or restructuring.
Therma Bright News
THRM FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was C$0.04 and its highest was C$0.24 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is C$3.19M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Apr 07, 2026 which is in 8 days.
How were Therma Bright’s earnings last quarter?
Currently, no data Available
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 58,002,876 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TSE:THRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Technical Analysis
Imagin Medical
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―
Options Prices
Currently, No data available
---